Transient Ischemic Attack Companies

Latest Transient Ischemic Attack Companies Update

• 
  May 2023: Bristol Myers Squibb and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen), jointly announced today that the U.S. Food and Drug Administration (FDA) has also granted Fast Track Designation to all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor. The designations encompass all three indication-seeking studies (Librexia STROKE, Librexia ACS, and Librexia AF) that involve administering patients as part of the Phase 3 Librexia development program. As the most comprehensive FXIa clinical development program to date, the Librexia program will furnish copious data from close to 50,000 patients, which is unparalleled. Despite significant advancements in the treatment of cardiovascular and stroke conditions during the last twenty years, millions of patients who could benefit from thrombotic events are still untreated or receive inadequate care due to the danger of hemorrhage.


• 
  May 2023: Fast Track Designation has been granted to Bayer's investigational drug asundexian by the U.S. Food and Drug Administration (FDA) for the potential prevention of stroke and systemic embolism in patients with atrial fibrillation (AF), the company announced in May 2023. This development follows the 2022 grant of asundexian its initial Fast Track Designation by the U.S. FDA for the purpose of preventing stroke in patients who have experienced a non-cardioembolic ischemic stroke. Asundexian is an investigational agent that has not received approval for any indication or use in any country from a health authority. Presently under assessment as a prospective oral Factor XIa (FXIa) inhibitor to be taken once daily for the prevention of thrombosis, its objective is to mitigate clot formation without impairing the body's capacity to react to hemorrhage.

• Koninklijke Philips NV (Netherlands)


• Stryker Corporation (US)


• Johnson & Johnson Services Inc (US)


• Boston Scientific Corporation (US)


• Sanofi (France)


• Bayer AG (Germany)


• Pfizer Inc (US)


• Siemens AG (US)


• F. Hoffmann-La Roche AG (Switzerland)


• GE Healthcare (UK)


• Penumbra Inc (California)


• Medtronic PLC (Ireland)


• Abbott Laboratories (US)


• Merck & Co., Inc (US)


• Boehringer Ingelheim GmbH (Germany)